Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$224M+121.4% YoY

Gross Profit

$138M61.7% margin

Operating Income

$63M28.3% margin

Net Income

$43M19.2% margin

EPS (Diluted)

$0.61

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

$73M

Free Cash Flow

$68M

Stock-Based Comp.

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$446M

Stockholders' Equity

$567M

Cash & Equivalents

$171M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$224M	$101M	+121.4%
Gross Profit	$138M	$46M	+199.5%
Operating Income	$63M	-$27M	+336.0%
Net Income	$43M	-$27M	+261.5%

Revenue Segments

Product

$218M33%

Radiopharmaceutical Oncology

$131M20%

PYLARIFY

$130M20%

Total Precision Diagnostics

$87M13%

DEFINITY

$62M9%

Techne Lite

$19M3%

License and Royalty Revenues

$6M1%

Strategic Partnerships And Other

$5M1%

Other Precision Diagnostics

$5M1%

Other Radiopharmaceutical Oncology

$928,0000%